TY - JOUR
T1 - Recent advances in clinical practice
T2 - advances in cross-sectional imaging in inflammatory bowel disease
AU - Rimola, Jordi
AU - Torres, Joana
AU - Kumar, Shankar
AU - Taylor, Stuart A.
AU - Kucharzik, Torsten
N1 - Funding Information:
JR has received grants from AbbVie and consulting fees from Boehringer Ingelheim, Janssen, Origo, Lument, Takeda and Alimentiv. JT has received grants from AbbVie and Janssen, advisory board fees and/or speaker fees from Janssen, Galapagos and Pfizer. SK has no declarations. SAT is a previous research consultant to Alimentiv. Shareholder in Motilent. TK has received grants from AbbVie, Janssen and Takeda, advisory board fees and/or speaker fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Ferring Arzneimittel, Galapagos, Gilead, Janssen, MSD Sharp & amp; Dome GmbH, Pfizer, Roche, Takeda Pharma and Vifor Pharma.
Publisher Copyright:
©
PY - 2022/8/4
Y1 - 2022/8/4
N2 - Endoscopy remains the reference standard for the diagnosis and assessment of patients with inflammatory bowel disease (IBD), but it has several important limitations. Cross-sectional imaging techniques such as magnetic resonance enterography (MRE) and intestinal ultrasound (IUS) are better tolerated and safer. Moreover, they can examine the entire bowel, even in patients with stenoses and/or severe inflammation. A variety of cross-sectional imaging activity scores strongly correlate with endoscopic measures of mucosal inflammation in the colon and terminal ileum. Unlike endoscopy, cross-sectional techniques allow complete visualisation of the small-bowel and assess for extraintestinal disease, which occurs in nearly half of patients with IBD. Extramural findings may predict outcomes better than endoscopic mucosal assessment, so cross-sectional techniques might help identify more relevant therapeutic targets. Coupled with their high sensitivity, these advantages have made MRE and IUS the primary non-invasive options for diagnosing and monitoring Crohn's disease; they are appropriate first-line investigations, and have become viable alternatives to colonoscopy. This review discusses cross-sectional imaging in IBD in current clinical practice as well as research lines that will define the future role of these techniques.
AB - Endoscopy remains the reference standard for the diagnosis and assessment of patients with inflammatory bowel disease (IBD), but it has several important limitations. Cross-sectional imaging techniques such as magnetic resonance enterography (MRE) and intestinal ultrasound (IUS) are better tolerated and safer. Moreover, they can examine the entire bowel, even in patients with stenoses and/or severe inflammation. A variety of cross-sectional imaging activity scores strongly correlate with endoscopic measures of mucosal inflammation in the colon and terminal ileum. Unlike endoscopy, cross-sectional techniques allow complete visualisation of the small-bowel and assess for extraintestinal disease, which occurs in nearly half of patients with IBD. Extramural findings may predict outcomes better than endoscopic mucosal assessment, so cross-sectional techniques might help identify more relevant therapeutic targets. Coupled with their high sensitivity, these advantages have made MRE and IUS the primary non-invasive options for diagnosing and monitoring Crohn's disease; they are appropriate first-line investigations, and have become viable alternatives to colonoscopy. This review discusses cross-sectional imaging in IBD in current clinical practice as well as research lines that will define the future role of these techniques.
KW - Crohn's disease
KW - Gastrointestinal ultrasound
KW - Inflammatory bowel disease
KW - Magnetic resonance imaging
UR - http://www.scopus.com/inward/record.url?scp=85135884651&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2021-326562
DO - 10.1136/gutjnl-2021-326562
M3 - Review article
C2 - 35927032
AN - SCOPUS:85135884651
SN - 0017-5749
VL - 71
SP - 2587
EP - 2597
JO - Gut
JF - Gut
IS - 12
ER -